Regeneron reports Q1 adjusted EPS $9.47, consensus $8.90

Reports Q1 revenue $3.6B, consensus $3.48B. “In the first quarter of this year, we were able to achieve strong double-digit growth on both the top and bottom line while continuing to invest significant resources in our portfolio of nearly 50 product candidates in clinical development,” said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron (REGN). “Additionally, we recently entered into an agreement with the U.S. government that aims to make progress toward lowering drug prices for American patients by promoting more balanced pricing with other wealthy nations – an approach for which Regeneron has long advocated.”